DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM

This study is to evaluate the safety and effectiveness of dendritic cell DC/MM fusion vaccine in combination with standard of care B-cell maturation antigen (BCMA) CAR-T cell therapy in participants with relapsed/refractory multiple myeloma. The names of the study drugs involved in this study are: * DC/MM fusion vaccine (a type of personalized cancer vaccine) * Granulocyte-macrophage colony-stimulating factor (GM-CSF) (a type of growth factor or hormone)

NCT Number	NCT07377435
Lead Sponsor	David Avigan Collaborators: The V Foundation
Conditions	Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma
Enrollment	25 participants
Start Date	2026-01-30
Primary Completion	2028-03-01 (estimated)
Study Completion	2032-03-01 (estimated)
Updated on ClinicalTrials.gov	2026-05-08